Oral administration of a small-molecule inhibitor of NLRP3 inflammasome, MCC950, effectively prevented dopaminergic degeneration and α-syn pathology, and alleviated motor behaviors in PD models (Gordon et al., 2018). Here, NLRP3 is linked to Parkinson disease.